arrow
A

Adam J. Olszewski

brown university
H指数:39
被引数:8,243

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-related quality of life with mosunetuzumab plus polatuzumab vedotin in R/R LBCL: Phase 3 SUNMO trial

mosunetuzumab联合polatuzumab vedotin在R/R LBCL中的健康相关生活质量:III期SUNMO试验

2026-10-120
OAAI
Peripheral CD8+ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma

外周CD8<sup>+</sup> T细胞克隆性和NK细胞扩增标志着惰性B细胞淋巴瘤对 mosunetuzumab 的早期反应

2026-09-120
OA
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma

一项随机II期研究:皮下注射mosunetuzumab联合polatuzumab vedotin与利妥昔单抗联合polatuzumab vedotin治疗复发或难治性大B细胞淋巴瘤患者的比较研究

2026-07-280
OAAI
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study

美国多中心回顾性研究:浆细胞样淋巴瘤的预后与治疗

2026-03-230
OAAI
BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

BrUOG360:一项关于Copanlisib联合Rucaparib治疗转移性去势抵抗性前列腺癌(mCRPC)患者的Ib/II期研究

2025-12-010
OA
HiJAKing the Hematopoietic System: A Low Frequency JAK2V617F Clone Drives Myeloproliferative Neoplasm Pathology

HiJAKing the Hematopoietic System: A Low Frequency JAK2V617F Clone Drives Myeloproliferative Neoplasm Pathology

Blood
IF23.1
2025-08-050
OA
Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data

利用真实世界数据表征接受利妥昔单抗联合吉西他滨和奥沙利铂(R-GemOx)治疗复发或难治性弥漫大B细胞淋巴瘤的美国患者人群

BLOOD
IF23.1
2024-11-050
PRE
Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

真实世界下Waldenström巨球蛋白血症一线治疗管理的结果:来自全球患者衍生数据登记库Whimsical的数据

BLOOD
IF23.1
2024-11-050
PRE
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study
2024-10-181
OAAI
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
2024-10-110
PRE
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
2024-06-280
OAAI
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
2023-12-1018
OAAI